ADC Therapeutics (ADCT) Q2 2026 Earnings Call: LOTIS-5 FDA Concerns, $219.1M CashTradingKey·Aug 14 at 03:04 AMADCT+3.80%
ADC Therapeutics SA | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 19.25 MEarnings Watch·Aug 13 at 08:18 AMADCT+3.80%
ADC Therapeutics posts corporate presentation highlighting Zynlonta growth opportunity in B-cell lymphomasPUBT·Aug 13 at 07:46 AMADCT+3.80%
ADC Therapeutics Q2 2026 Earnings: Lower Spending Narrows the LossTradingKey·Aug 13 at 06:44 AMADCT+3.80%
ADCT: Q2 2026 delivered stable sales, improved losses, and regulatory challenges for ZYNLONTAQuartr·Aug 13 at 06:41 AMADCT+3.80%
ADC Therapeutics Q2 FY26 net loss narrows 70.75% to $16.6 million; revenue rises 2.99% to $19.25 millionPUBT·Aug 13 at 06:32 AMADCT+3.80%
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Whybenzinga_article·Jul 21 at 02:52 PMRGNX-3.07%ADCT+3.80%
